

Neuroprotection

Part II: Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

October 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist qualifications. He received graduate training in both Europe and USA and has held academic positions in several countries. He has been involved in biotechnology/pharmaceutical industry since 1989 and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK since 2000. After his retirement from neurosurgery, he is a consultant at Jain PharmaBiotech in Basel, Switzerland.

Prof. Jain's 478 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. As associate editor and contributing author of MedLink Neurology (San Diego, California), he is responsible for writing and yearly updating of 143 articles for continuing education of neurologists in an electronic encyclopedia of neurology. He has also written the Textbook of Gene Therapy, which was translated into Chinese, and a book on gene therapy companies published in 2000 by John Wiley & Sons. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer, 2008; 2nd ed 2014, 3rd ed 2019 is in preparation) and "Drug Delivery to the Central Nervous System", (Springer/Humana 2010). His recent books include "Handbook of Nanomedicine" (Springer/Humana 2008, Chinese edition by Peking University Press, 2011; 3rd ed Springer 2017), "Drug-induced Neurological Disorders, 3rd ed" (Hogrefe 2011), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd edn 2019, in preparation), and "Applications of Biotechnology in Neurology" (Springer 2013). He has edited "Applied Neurogenomics" (Springer 2015).

Prof. Jain has been involved in various neuroprotective strategies during his active neurosurgical career including use of hypothermia, hyperbaric oxygen and induced coma. He has a personal experience of methods of neuroprotection used in the care of patients with stroke and CNS trauma as well as during neurosurgical operations.

October 2018 (first edition in April 2000)
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

14. Markets for Neuroprotective Therapies	4
Introduction	4
The financial burden of CNS damage	4
Markets for neuroprotective therapies	4
Markets according to therapeutic areas.....	4
<i>Stroke</i>	5
<i>CNS injury</i>	5
<i>Alzheimer disease</i>	5
<i>Parkinson disease</i>	6
<i>Multiple sclerosis</i>	6
<i>Epilepsy</i>	6
Values of neuroprotective therapies in major world markets.....	6
Unmet needs in neuroprotectives.....	7
Future of neuroprotective therapies	9
Challenges in neuroprotective drug development	9
Promising areas of research in neuroprotection.....	9
<i>Autoreactive antibodies</i>	10
<i>Biological therapies for neuroprotection</i>	10
<i>Multidisciplinary approaches to neuroprotection</i>	10
15. Companies Developing Neuroprotective Therapies	11
Introduction	11
Profiles of companies	11
Collaborations	161
16. References	167

Tables

Table 14-1: Neuroprotective market values 2017-2027	5
Table 14-2: Values of neuroprotective therapies in major world markets from 2017-26	6
Table 15-1: Collaborations of companies in the area of neuroprotection.....	161

Figures

Figure 14-1: Unmet therapeutic needs in neuroprotective therapies	8
---	---